CLINICAL CASE OF TOCILIZUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
https://doi.org/10.15690/pf.v11i1.905
Abstract
The article presents a case of successful use of a preparation of monoclonal antibodies to interleukin 6 receptors (tocilizumab) at a
severe systemic juvenile idiopathic arthritis. Tocilizumab treatment promptly provided decrease of clinical and laboratory parameters
of the disease activity, increase in the child’s physical activity, systemic juvenile idiopathic arthritis remission development and allowed avoiding per os prescription of glucocorticoids.
severe systemic juvenile idiopathic arthritis. Tocilizumab treatment promptly provided decrease of clinical and laboratory parameters
of the disease activity, increase in the child’s physical activity, systemic juvenile idiopathic arthritis remission development and allowed avoiding per os prescription of glucocorticoids.
About the Authors
O. L. Lomakina
Scientific Center of Children's Health
Russian Federation
graduate student of the rheumatology department of Scientific Center of Children's Health
Russian Federation
graduate student of the rheumatology department of Scientific Center of Children's Health
E. I. Alexeyeva
Scientific Center of Children’s Health, Moscow, Russian Federation
First Sechenov Moscow State Medical University, Russian Federation
Russian Federation
Russian Federation
R. V. Denisova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
T. V. Sleptsova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
A. N. Fetisova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Cassidy J. T., Petty R. E., Laxer R. M., Lindsley C. B. Textbook of pediatric rheumatology. 6th ed. Saunders Elsevier, Philadelphia, 2011. 794 р.
2. Alexeeva E.I., Valieva S.I., Bzarova T.M. Efficacy and safety of refresher rituximab treatment courses of refractory juvenile idiopathic arthritis. Voprosy sovremennoi pediatrii = Current pediatrics. 2009; 8 (5): 14–25.
3. Bzarova T.M., Alexeeva E.I., Peterkova V.A. Role of disease and antirheumatic therapy factors in dwarfism development in children with juvenile idiopathic arthritis. Voprosy sovremennoi pediatrii = Current pediatrics. 2006; 5 (5): 13–18.
4. Kelly A., Ramanan A. V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr. Opin. Rheumatol. 2007; 19: 477–81.
5. Cortis E., Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl. 2006; 95: 38–41.
6. Rothwell N. J., Busbridge N. J., Lefeuvre R. A., Hardwick A. J. Interleukin-6 is a centrally acting endogenous pyrogen in the rat. Can. J. Physiol. Pharmacol. 1991; 69: 1465–1469.
7. Castell J. V., Gomez-Lechon M. J., David M. et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988; 232: 347–350.
8. Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004; 113: 1271–1276.
9. Ikebuchi K., Wong G. G., Clark S. C., Ihle J. N., Hirai Y., Ogawa M. Interleukin-6 enhancement of interleukin-3-dependent proliferationof multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci USA. 1987; 84: 9035–9039.
10. Kimura H., Ishibashi T., Uchida T., Maruyama Y., Friese P.,Burstein S. A. Interleukin-6 is a differentiation factor for human megakaryocytes in vitro. Eur. J. Immunol. 1990; 20: 1927–1931.
11. Tsigos C., Papankolaou D. A., Defensor R., Mitsiadis C. S., Kyrou I., Chrousos G. P. Dose-effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997; 66: 54–62.
12. Heliovaara M. K., Teppo A. M., Karonen S. L., Tuominen J. A., Ebeling P. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes Metab. 2005; 7: 729–736.
13. European Medicines Agency. RoActemra (tocilizumab): summary of product characteristics [online]. Available at: http://www. ema.europa.eu/docs/en_GB/document_library/EPAR
14. Chugai Pharmactutical Co. Actemra, a humanized antihuman IL-6 receptor monoclonal antibody obtained approval for indications of rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis [media release]. Available at: http://www.chugai-pharm.co.jp/hc/ss/english/index.html
15. Imagawa T., Ozawa R., Miyamae T. et al. Efficacy and safety in 48-week treatment of tocilizumab in children with polyaticular course JIA with polyarticlar or olygoarticular onset. Ann. Rheum. Dis. 2007; 66 (Suppl. II): 550.
16. Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 715.
17. Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 720.
18. Yokota S., Imagawa T., Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.
19. Quartier P., Maire D., Souabni L. Efficacy and safety of tocilizumab in systemic onset juvenile idiopathic arthritis in French centers [FRI0462]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 506.
20. Kaneko U., Imagawa T., Kishi T. Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 719.
21. Baranov A.A., Alexeeva E.I., Denisova R.V., Valieva S.I., Bzarova T.M., Isaeva K.B., Sleptsova T.V., Mitenko E.V., Chistyakova E.G., Fetisova A.N. Retrospective analysis of tocilizumab efficacy and safety in patients with severe systemic juvenile idiopathic arthritis: 12 months of observation. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12 (2): 26–34.
Review
For citations:
Lomakina O.L., Alexeyeva E.I., Denisova R.V., Sleptsova T.V., Fetisova A.N. CLINICAL CASE OF TOCILIZUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. Pediatric pharmacology. 2014;11(1):93-96. https://doi.org/10.15690/pf.v11i1.905
Views:
652
Email this article 